Currently, epidermal growth factor receptor (EGFR) is the major target for therapeutic antibodies and inhibitor-based palliative treatment regimens aiming at controlling recurrent and metastatic disease in HNSCC patients. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.